Key result
A COMPASS-CAT score of ≥ 7 points was associated with a significantly higher risk of venous thromboembolism in lung cancer patients (RR 4.68; 95% CI 1.05-20.80).
Why the study?
Venous thromboembolism incidence is high in lung cancer patients, making risk stratification models vital for targeted thromboprophylaxis.
Do VTE risk assessment tools accurately predict venous thromboembolism in ambulatory patients with lung cancer?
Meta-Analysis (n=123,493)
Do VTE risk assessment tools accurately predict venous thromboembolism in ambulatory patients with lung cancer?
Relative Risk: 4.68 (95% CI 1.05–20.8)
The COMPASS-CAT score shows better discriminatory capability than the Khorana score for predicting VTE in ambulatory lung cancer patients, highlighting the need for disease-specific risk tools.
May inform targeted thromboprophylaxis in lung cancer; leaves open optimal model selection and validation.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2024) conducted a meta-analysis in Lung cancer (n=123,493). COMPASS-CAT score ≥ 7 points vs. COMPASS-CAT score < 7 points was evaluated on Venous thromboembolism (VTE) (RR 4.68, 95% CI 1.05-20.80). A COMPASS-CAT score of ≥ 7 points was associated with a significantly higher risk of venous thromboembolism in lung cancer patients (RR 4.68; 95% CI 1.05-20.80).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: